Impaired beta‐cell function is a recognized cornerstone of diabetes pathophysiology.
Estimates of insulin secretory capacity are useful to inform clinical practice, helping to …

Background Semaglutide is an effective treatment for type 2 diabetes; however, 20–30% of
patients given semaglutide 1· 0 mg do not reach glycaemic treatment goals. We aimed to …

Aim To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in
patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD‐11 trial …

Aims To evaluate the efficacy and safety of oral semaglutide versus comparators by patient
characteristic subgroups in patients with type 2 diabetes. Materials and Methods Change …

Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist.
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …

Abstract Aims/Introduction To assess the impact of baseline characteristics on the efficacy
and safety of oral semaglutide in Japanese patients with type 2 diabetes. Materials and …

Purpose Registered trials and real-world evidence (RWE) studies provided evidence on the
efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk …

Early and intensive management of type 2 diabetes has been shown to delay disease
progression, reduce the risk of cardiorenal complications and prolong time to treatment …

Aims To understand glucagon-like peptide-1 receptor agonist (GLP-1RA) use in patients
with type 2 diabetes (T2D) in Japan. Methods Characteristics of people receiving GLP-1RAs …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used to address multiple
aspects of type 2 diabetes mellitus (T2DM) management, including glycaemic control …